Condition
Metastatic Triple Negative Breast Cancers
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Not Yet Recruiting1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07458113Phase 2Not Yet RecruitingPrimary
Sac-TMT for Active TNBC Brain Metastases
NCT06449222Phase 2Active Not Recruiting
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06774027Recruiting
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
NCT05035745Phase 1Recruiting
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Showing all 4 trials